Glaxo Goes After Hearty Boost From New Drugs

Birmingham Post › April 14, 2004

Linked as:

Summary

GlaxoSmithKline has boosted its portfolio with a 453 million euros (pounds 297.5 million) deal for two treatments of acute heart disease.

The group yesterday struck a deal with Sanofi-Synthelabo to buy injectable drugs Fraxiparine and Arixtra, which have combined annual sales of 343 million euros (pounds 225.2 million).

See the full content of this document

Extract

Glaxo Goes After Hearty Boost From New Drugs

The acquisition hinges on Sanofi winning its hostile pounds 33.1 billion b...

See the full content of this document

Sponsored links

ver las páginas en versión mobile | web

ver las páginas en versión mobile | web

© Copyright 2012, vLex. All Rights Reserved.

Language

Contents in vLex United Kingdom

Explore vLex

For Professionals

For Partners

Company

Other documents:

Lcnb Corp Slates Quarterly Dividend Payout for 15 Dec | Deal Snapshot: Integralis Agrees to Be Taken Over by Japanese Ntt for Eur75m | Can t Look to Future Until Hicks and Gillett Get Boot | Primary Pupils Have the Wow Factor | Peripheral Arterial Disease Represents a Significant and Rapidly Growing Market Opportunity for In... | DSP Group Inc. Third Quarter 2004 Earnings Release and Conference Call. | Valeant Pharmaceuticals to Initiate Clinical Development of Viramidine(R) in Japa... | Security Tops List of Technologies that Will Have Greatest Impact in 2007 CompTIA Web Poll Finds.